Physician profile
Chloe E Yun
NPI 1558042663
$803.05
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $519 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $228.59 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $131.46 | 2024 | Tremfya |
| Almirall LLC | $88.82 | 2024-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $82.08 | 2024 | Vtama |
| Leo Pharma INC. | $64.75 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $53.72 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $34.67 | 2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $23.02 | 2025 | |
| Mimedx Group, INC. | $20.83 | 2024 | |
| Incyte Corporation | $20.00 | 2024 | Opzelura |
| Galderma Laboratories, L.P. | $19.51 | 2025 | Nemluvio |
| Journey Medical Corporation | $18.94 | 2025 | |
| Abbvie INC. | $16.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.